{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:18:41Z","timestamp":1792556321853,"version":"4.5.0"},"reference-count":29,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.2967\/jnumed.123.265546","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T15:00:30Z","timestamp":1692889230000},"page":"1574-1580","source":"Crossref","is-referenced-by-count":37,"title":["Clinical Experience with [<sup>225<\/sup>Ac]Ac-PSMA Treatment in Patients with [<sup>177<\/sup>Lu]Lu-PSMA\u2013Refractory Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"64","author":[{"given":"Nalan","family":"Alan-Selcuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Beydagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Ocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala B.","family":"Oven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turkay","family":"Toklu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipek","family":"Karaaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan","family":"Akcay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Sonmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Kabasakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"2023100305301111000_64.10.1574.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"2023100305301111000_64.10.1574.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"2023100305301111000_64.10.1574.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"2023100305301111000_64.10.1574.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"2023100305301111000_64.10.1574.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"2023100305301111000_64.10.1574.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2023100305301111000_64.10.1574.7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bju.15143","article-title":"Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option","volume":"126","author":"Mayor","year":"2020","journal-title":"BJU Int."},{"key":"2023100305301111000_64.10.1574.8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023100305301111000_64.10.1574.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023100305301111000_64.10.1574.10","doi-asserted-by":"crossref","first-page":"796657","DOI":"10.3389\/fonc.2022.796657","article-title":"Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol."},{"key":"2023100305301111000_64.10.1574.11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4161\/cbt.4.7.1868","article-title":"In vivo studies of pharmacokinetics and efficacy of bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27","volume":"4","author":"Rizvi","year":"2005","journal-title":"Cancer Biol Ther."},{"key":"2023100305301111000_64.10.1574.12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/pharmaceutics13050715","article-title":"Development of [225Ac]Ac-PSMA-I&T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC","volume":"13","author":"Hooijman","year":"2021","journal-title":"Pharmaceutics."},{"key":"2023100305301111000_64.10.1574.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2023100305301111000_64.10.1574.14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023100305301111000_64.10.1574.15","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics."},{"key":"2023100305301111000_64.10.1574.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251017"},{"key":"2023100305301111000_64.10.1574.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229229"},{"key":"2023100305301111000_64.10.1574.18","doi-asserted-by":"crossref","first-page":"729.e7","DOI":"10.1016\/j.urolonc.2020.12.002","article-title":"Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy","volume":"39","author":"van der Doelen","year":"2021","journal-title":"Urol Oncol."},{"key":"2023100305301111000_64.10.1574.19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/ijnm.IJNM_130_20","article-title":"Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer","volume":"35","author":"Satapathy","year":"2020","journal-title":"Indian J Nucl Med."},{"key":"2023100305301111000_64.10.1574.20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol."},{"key":"2023100305301111000_64.10.1574.21","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","article-title":"Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer","volume":"49","author":"Lawal","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023100305301111000_64.10.1574.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"2023100305301111000_64.10.1574.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233817"},{"key":"2023100305301111000_64.10.1574.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0125"},{"key":"2023100305301111000_64.10.1574.25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/pharmaceutics13050722","article-title":"Efficacy and safety of [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis","volume":"13","author":"Rosar","year":"2021","journal-title":"Pharmaceutics."},{"key":"2023100305301111000_64.10.1574.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203539"},{"key":"2023100305301111000_64.10.1574.27","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","article-title":"Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"49","author":"Rosar","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023100305301111000_64.10.1574.28","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3390\/pharmaceutics14102166","article-title":"Advances in 177Lu-PSMA and 225Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate cancer","volume":"14","author":"Ling","year":"2022","journal-title":"Pharmaceutics."},{"key":"2023100305301111000_64.10.1574.29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","article-title":"Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT","volume":"46","author":"Rathke","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T12:32:59Z","timestamp":1696336379000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,3]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.2967\/jnumed.123.265546"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265546","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}